Sign In
Buy ZYME
$24.35
+0.240 (+1.00%)
At Close: Jun 03, 2026
Zymeworks Inc. (ZYME) Flat As Market Sinks: What You Should Know
07:34pm, Wednesday, 22'nd Feb 2023
Zymeworks Inc. (ZYME) closed the most recent trading day at $8.57, making no change from the previous trading session.
Zymeworks Announces Participation in Upcoming Investor Conferences
08:30am, Wednesday, 25'th Jan 2023
VANCOUVER, British Columbia--( BUSINESS WIRE )--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management
Zymeworks shares gain on promising data for cancer drug in development with Jazz Pharmaceuticals
08:07am, Thursday, 19'th Jan 2023
Shares of Zymeworks Inc. ZYME, rallied 14% in premarket trading on Thursday after the company and Jazz Pharmaceuticals Inc. JAZZ, -0.58% said their experimental cancer drug had an overall survival rat
MDA Breakout Stocks Week 3 - January 2023: High-Frequency Gainers To Give You An Edge
06:24am, Sunday, 15'th Jan 2023
Two new Breakout Stocks for Week 3 with better than 10% short-term upside and two Dow 30 Picks. Average cumulative returns for 2023 are +21.37% YTD. This week 2 of 4 high-frequency breakout picks gain
Zymeworks (ZYME) Stock Up 29% in Three Months: Here's Why
12:21pm, Wednesday, 28'th Dec 2022
Zymeworks (ZYME) recently entered a collaboration with Jazz Pharmaceuticals (JAZZ) for its lead pipeline candidate. This has been a significant catalyst for the stock.
Zymeworks Inc. (ZYME) Upgraded to Buy: Here's What You Should Know
01:32pm, Friday, 23'rd Dec 2022
Zymeworks Inc. (ZYME) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zymeworks Announces Participation in Upcoming Investor Conference
07:30am, Wednesday, 21'st Dec 2022
VANCOUVER, British Columbia--( BUSINESS WIRE )--Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management
Why Zymeworks Inc. (ZYME) Might be Well Poised for a Surge
01:32pm, Thursday, 24'th Nov 2022
Zymeworks Inc. (ZYME) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zymeworks Announces Participation in Upcoming Investor Conference
08:30am, Tuesday, 22'nd Nov 2022
VANCOUVER, British Columbia--( BUSINESS WIRE )--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates
10:45pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 23.40% and 44.44%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) Q3 2022 Earnings Call Transcript
08:24pm, Tuesday, 08'th Nov 2022
Zymeworks Inc. (NYSE:ZYME ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Jack Spinks - Head of Investor Relations Neil Klompas - President & COO Kenneth Galbraith -
Relentless Zymeworks stock eyes a breakout from channel. Buyers should keep watch
02:12pm, Friday, 04'th Nov 2022
Zymeworks Inc. (NYSE:ZYME) could be one of the best biotech stocks to buy in November. The stock, which has crashed by 55.71% year-to-date, trades within narrow ranges, but the upside potential is gro
Why Rogers Shares Are Trading Sharply Lower; Here Are 33 Stocks Moving Premarket
11:58am, Wednesday, 02'nd Nov 2022 Benzinga
Gainers
Avinger, Inc. (NASDAQ: AVGR) rose 32% to $1.36 in pre-market trading. Avinger is expected to release its financial results for the third quarter on Wednesday, November 9, 2022.
Arcturus Thera
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
02:27pm, Tuesday, 01'st Nov 2022 Benzinga
Upgrades
For AnaptysBio Inc (NASDAQ:ANAB), Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio earned $1.15 in the second quarter, compared to $0.02 in the year-ago quarter. The sto
Why Shares of Zymeworks Rose 12.18% on Monday
08:42pm, Monday, 31'st Oct 2022 The Motley Fool
The biotech stock's shares may have been pushed by a short squeeze.
